280752-46-7

Upstream product

• 1122-41-4 2,4-dichlorobenzenethiol 
• 89-98-5 2-chloro-benzaldehyde 
• 552-89-6 2-nitro-benzaldehyde 

Downstream Products

• 280752-47-8 (2E)-3-{2-[(2,4-dichlorophenyl)thio]phenyl}acrylic acid 
• 1028268-25-8 (E)-3-[2-(2,4-Dichloro-phenylsulfanyl)-phenyl]-acryloyl chloride 
• 710960-78-4 ethyl (2E)-3-{2-[(2,4-dichlorophenyl)thio]phenyl}acrylate 
• 1140506-59-7 2-(2,4-dichlorobenzenesulfonyl)benzaldehyde 

Relevant academic research and scientific papers

INDOLIZINE DERIVATIVES WITH CRTH2 RECEPTOR AFFINITY FOR THE TREATMENT OF INFLAMMATORY DISEASES

Compounds of formula (I) are ligands of the CRTH2 receptor, useful in the treatment of, for example, inflammatory respiratory disease: R1 is fluoro, chloro, CN or CF3; R2 is hydrogen, fluoro or chloro; X is -CH2-, or - S(O)n-; Ar1 is phenyl or 5- or 6-membered heteroaryl, wherein the phenyl or heteroaryl rings are optionally substituted with one substituent selected from fluoro, chloro, CN, -O(C1-C3alkyi) or C1-C3alkyl, the latter two groups being optionally substituted by one or more fluoro atoms; Y is -CR3R4-, -C(O)-, -O-, -S(O)2- or -NR3-; R3 and R4 independently represent hydrogen or C1-C3alkyl; Ar2 is phenyl or 5- or 6- membered heteroaryl, wherein the phenyl or heteroaryl rings are optionally substituted by one or more substituents independently selected from halogen, - CN, -S(O)nR5, -S(O)2NR6R7, -NR6S(O)2R5 -NR6R7, -NR6COR5, -CONR6R7, -COR5, -OR6, C1- C6alkyl or C3-C7cycloalkyl, the latter two groups being optionally substituted by one or more fluoro atoms; R5 is C1-C6alkyl or C3-C7cycloalkyl, optionally substituted by one or more fluoro atoms; R6 and R7 independently represent hydrogen, C1-C6alkyl or C3-C7cycloalkyl, the latter two groups being optionally substituted by one or more fluoro atoms; and n is O, 1 or 2.

Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds

The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immunune diseases, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds

The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases and cerebral vasospasm, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

Novel amides that activate soluble guanylate cyclase

Compounds of formula (I) are useful for increasing cGMP levels in a mammal.

Novel amides that activate soluble guanylate cyclase

Compounds of formula (I) are useful for increasing cGMP levels in a mammal.

Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 1. Identification of an additional binding pocket based on an anilino diaryl sulfide lead

The interaction between leukocyte function-associated antigen-1 (LFA-1), a member of the β2-integrin family of adhesion molecules, and intracellular adhesion molecule ICAM-1 (cd54) is thought to play a critical role in the inflammatory process.

Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds

The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response i